| 2025-12-04 |
详情>>
内部人交易：
Harlow John B. Jr.股份增加424536.00股
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本23906.34万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.43美元,归母净利润-8451.3万美元,同比去年增长-177.76%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘前发布财报
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.27美元,归母净利润-5318万美元,同比去年增长-5789.26%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.21美元,归母净利润-4045.5万美元,同比去年增长-166.3%
|
| 2025-04-17 |
股东大会：
将于2025-05-29召开股东大会
会议内容 ▼▲
- 1.To elect two Class III director nominees to our Board of Directors, Jay P. Shepard and Seth H.Z. Fischer, each to hold office until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan, as amended (the “2022 Plan”), to increase the aggregate number of shares of common stock authorized for issuance under the 2022 Plan by 6,250,000 shares;
5.To transact any other business that may properly come before the Annual Meeting (including adjournments and postponements thereof).
|
| 2025-03-07 |
详情>>
业绩披露：
2024年年报每股收益-0.28美元,归母净利润-5174.5万美元,同比去年增长75.27%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.17美元,归母净利润-3042.7万美元,同比去年增长80.10%
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-0.01美元,归母净利润-90.3万美元,同比去年增长99.19%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益0.36美元,归母净利润6102.20万美元,同比去年增长198.87%
|
| 2024-04-11 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect two Class II director nominees to our Board of Directors, Antonio M. Gotto Jr., M.D., D.Phil., and Nicole Vitullo, each to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan, as amended (the “2022 Plan”) to increase the aggregate number of shares of common stock authorized for issuance under the 2022 Plan by 6,250,000 shares;
5.To approve an amendment to the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended (the "ESPP") to increase the number of shares of common stock reserved for future issuance under the ESPP by 6,175,000 shares;
6.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2024-02-27 |
详情>>
业绩披露：
2023年年报每股收益-2.03美元,归母净利润-2.09亿美元,同比去年增长10.45%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.53美元,归母净利润-1.53亿美元,同比去年增长14.18%
|
| 2023-08-01 |
详情>>
业绩披露：
2023年中报每股收益-1.19美元,归母净利润-1.12亿美元,同比去年增长9.26%
|
| 2023-04-13 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.To elect four Class I directors, J. Martin Carroll, Sheldon L. Koenig, Stephen Rocamboli and Tracy M. Woody to hold office until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
4.To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan (the “2022 Plan”) to increase the aggregate number of shares of common stock authorized for issuance under the 2022 Plan by 6,250,000 shares;
5.To amend our Charter to increase the authorized shares of common stock from 240,000,000 to 480,000,000;
6.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2022-08-18 |
股东大会：
将于2022-09-20召开股东大会
会议内容 ▼▲
- 1.To approve the ratification of the prior filing and effectiveness of the certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on May 26, 2022 (the “Share Increase Amendment”) and the increase in the number of shares of our authorized common stock, par value $0.001 per share (the “Common Stock”), effected thereby (the “Ratification”).
2.To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Ratification (the “Adjournment Proposal”).
|
| 2022-04-14 |
股东大会：
将于2022-05-26召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, Alan Fuhrman, Jay Shepard and Seth H.Z. Fischer to hold office until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To hold a stockholder advisory vote to determine the frequency of future stockholder advisory votes on the compensation of our named executive officers;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
5.To approve the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan;
6.To amend our Charter to increase the authorized shares of common stock from 120,000,000 to 240,000,000;
7.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2021-11-24 |
复牌提示：
2021-11-23 15:55:12 停牌，复牌日期 2021-11-23 16:00:00
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-15 |
股东大会：
将于2021-05-27召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, Jeffrey Berkowitz, J.D., Antonio M. Gotto Jr., M.D., D.Phil. and Nicole Vitullo to hold office until the 2024 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
5.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2020-04-16 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect four Class I directors, Daniel Janney, Tim M. Mayleben, Mark E. McGovern, M.D., FACC, FACP, and Tracy M. Woody to hold office until the 2023 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.To approve the 2020 Employee Stock Purchase Plan;
5.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2019-04-18 |
股东大会：
将于2019-05-29召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, Scott Braunstein, M.D. and Jay P. Shepard to hold office until the 2022 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2018-04-13 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, Jeffrey Berkowitz, J.D., Antonio M. Gotto Jr., M.D., D.Phil., and Nicole Vitullo to hold office until the 2021 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
4.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2017-03-06 |
股东大会：
将于2017-04-17召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors, Daniel Janney, Tim M. Mayleben and Mark E. McGovern, M.D., to hold office until the 2020 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To approve, on an advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
4.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2016-04-28 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1. To elect three Class III directors, Scott Braunstein, M.D., Dov A. Goldstein, M.D. and Roger S. Newton, Ph.D., FAHA, to hold office until the 2019 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To hold a stockholder advisory vote on the compensation paid to our named executive officers;
4. To hold a stockholder advisory vote to determine the frequency of future stockholder advisory votes on the compensation paid to our named executive officers;
5. To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|